circle with dots in blue
circle with dots in blue
circle with dots in blue
circle with dots in blue

Same-day sepsis diagnostics directly from blood

inbiome is a pioneer in molecular diagnostics. Our patented Molecular Culture technology enables drastically faster bacterial diagnostics and microbiome analysis. This creates the opportunity to radically accelerate human healthcare.

Request Molecular Culture
inbiome magnifier display-block

Diagnostic certainty takes days. Treatment decisions cannot wait.

Delayed identification

Culture-first workflows delay actionable results for days, while treatment decisions must already be made.
inbiome yellow swoosh

Antibiotics reduce culture sensitivity

Many patients receive antibiotics before cultures become informative, leading to culture-negative uncertainty.

Negative confirmation takes too long

Clinicians often continue broad-spectrum therapy simply because infection cannot yet be ruled out.

inBiome’s Molecular Culture is designed for the earliest and most uncertain phase of sepsis care.

Broad Spectrum

Identify 300+ bacterial species at the species level directly from blood.

Broad detection beyond fixed panels increases confidence in both positive and negative results.

inbiome yellow swoosh

Fits Your Workflow

Compatible with standard laboratory equipment and workflows with up to 10 mL input volume.

Designed for molecular laboratory environments without requiring a closed proprietary ecosystem.

Trust Your Negatives

Detect as low as 1-5 CFU and rapidly rule out bacterial infection.

Support earlier de-escalation and reduce unnecessary broad-spectrum antibiotic exposure.

More about Molecular Culture®
inbiome’s platform is designed to support faster and more confident clinical decisions during the earliest and most uncertain phase of sepsis care. By enabling same-day bacterial identification directly from blood, the platform supports earlier targeted therapy, helping clinicians refine treatment sooner in high-risk patients where every hour matters.
At the same time, trustworthy negative results enable confident de-escalation, reducing unnecessary broad-spectrum antibiotic exposure when bacterial infection is unlikely. Because Molecular Culture® detects bacterial DNA rather than relying solely on organism growth, it maintains diagnostic value after antibiotics, preserving clinical relevance in patients in whom traditional cultures often lose sensitivity after treatment initiation.
More about Molecular Culture®

Decisions before culture results

Designed for seamless implementation in standard laboratory workflows, inbiome provides transparent preprocessing requirements, SOP integration support, validation guidance, and audit-ready documentation to support rapid onboarding and regulatory confidence.

The goal? Help clinicians make informed treatment decisions hours to days before traditional culture results become informative.

Optimized for Joint Aspirates.

Molecular Culture® is now optimized for Infectious Disease Diagnostics in joint aspirates. Creating groundbreaking results and reactions:

Paul Savelkoul

“With Molecular Culture we can deliver faster and more accurate diagnostics for patients with joint infections”

Prof. Dr. P.H.M. Savelkoul, Head of Clinical Microbiology
Maastricht University Medical Centre